10x Genomics Stock Z Score
| TXG Stock | USD 13.29 0.03 0.23% |
10X | Z Score |
10X Genomics Company Z Score Analysis
10X Genomics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
10X Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for 10X Genomics is extremely important. It helps to project a fair market value of 10X Stock properly, considering its historical fundamentals such as Z Score. Since 10X Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 10X Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 10X Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, 10X Genomics has a Z Score of 0.0. This is 100.0% lower than that of the Life Sciences Tools & Services sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.
10X Genomics Current Valuation Drivers
We derive many important indicators used in calculating different scores of 10X Genomics from analyzing 10X Genomics' financial statements. These drivers represent accounts that assess 10X Genomics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of 10X Genomics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.0B | 14.3B | 16.4B | 4.1B | 6.6B | 5.2B | |
| Enterprise Value | 2.6B | 13.7B | 15.9B | 4.0B | 6.3B | 5.0B |
10X Genomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 10X Genomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 10X Genomics' managers, analysts, and investors.Environmental | Governance | Social |
10X Genomics Institutional Holders
Institutional Holdings refers to the ownership stake in 10X Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of 10X Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing 10X Genomics' value.| Shares | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 1.9 M | Geode Capital Management, Llc | 2024-06-30 | 1.8 M | State Street Corp | 2024-06-30 | 1.6 M | Voloridge Investment Management, Llc | 2024-06-30 | 1.4 M | Millennium Management Llc | 2024-06-30 | 1.4 M | Norges Bank | 2024-06-30 | 991.1 K | Capital World Investors | 2024-09-30 | 793.3 K | Bank Of America Corp | 2024-06-30 | 736.5 K | Soleus Capital Management, L.p. | 2024-06-30 | 719 K | Fmr Inc | 2024-09-30 | 13.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11.5 M |
10X Fundamentals
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 1.3 B | ||||
| Shares Outstanding | 107 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 94.38 % | ||||
| Number Of Shares Shorted | 7.61 M | ||||
| Price To Book | 2.23 X | ||||
| Price To Sales | 2.55 X | ||||
| Revenue | 618.73 M | ||||
| Gross Profit | 396.02 M | ||||
| EBITDA | (205.11 M) | ||||
| Net Income | (255.1 M) | ||||
| Cash And Equivalents | 499.73 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 95.37 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 5.97 X | ||||
| Cash Flow From Operations | (15.2 M) | ||||
| Short Ratio | 3.26 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Price To Earnings To Growth | 0.13 X | ||||
| Target Price | 20.29 | ||||
| Number Of Employees | 1.26 K | ||||
| Beta | 1.87 | ||||
| Market Capitalization | 1.61 B | ||||
| Total Asset | 965.14 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 468.86 M | ||||
| Net Asset | 965.14 M |
About 10X Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out 10X Genomics Piotroski F Score and 10X Genomics Valuation analysis. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 5.261 | Quarterly Revenue Growth (0.01) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.